Christine Solberg Strahl, PharmD, Specialty Pharmacy Program Manager, HealthPartners, says that by managing specialty drugs before utilization patterns are established there is less member and provider dissatisfaction.
Christine Solberg Strahl, PharmD, Specialty Pharmacy Program Manager, HealthPartners, says that by managing specialty drugs before utilization patterns are established there is less member and provider dissatisfaction. Using medical injectables as an example, Dr Strahl says that there are coding and pricing issues associated when managing new specialty drugs that are administered on the specialty benefit.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More